Thermo Scientific Opens New GMP Clinical Services Facility in Singapore
News Nov 21, 2015
To address the growing global demand for clinical services, Thermo Fisher Scientific has announced the official opening of its new GMP facility. Having established its first clinical services facility in Singapore in 2001, the move to this newly built facility will meet the growing demand for clinical supply services in the region.
The new site will provide both regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies - from GMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to returns management.
Located in Toh Guan Road, Jurong East - the hub for Singapore's biomedical and pharmaceutical companies - the new facility is nearly 70,000 square feet (6,500sqm), more than 60 percent larger than the previous site and double the cold chain capacity.
The clinical services facility is also well-equipped with improved technologies and operational tools to serve a growing need for clinical supplies and trials in the region. This includes a larger storage system for its clinical supplies, a new climatic control energy consumption system that reduces the facility's carbon footprint, and an overall building monitoring system that provides staff with timely updates on the facility's conditions.
"Asia Pacific continues to be our fastest-growing market and a central contributor to our growth," said Leon Wyszkowski, Thermo Fisher's vice president of clinical services for North America and facility network. "For nearly 15 years, Singapore has been the central hub for our Asia-Pacific operations, due to its strategic location. With the opening of our larger and well-equipped facility, we aim to continue to build on our Singapore facility further and on the expertise of our local team, to strengthen our regional and global presence in the clinical supplies industry."
Chow Wengyin, General Manager, Fisher Clinical Services, Singapore says "We believe that our continued expansion and move to this new 70,000ft/2 GMP facility is testament to our operational excellence, our flexibility and the breadth of services that we provide to support the continuum of supply chain needs within a clinical trial setting seamlessly and cost-effectively. We invite you to visit us in Singapore."
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE